Clinical Trials Using Talabostat Mesylate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Talabostat Mesylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC.

    An open-label, multicenter, Phase 1b / 2 study to determine the composite response rate of BXCL701 administered orally and daily, combined wit PEMBRO, in patients with mCRPC enrolled in Stage 2, with either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma phenotype (Cohort B). This study will also assess other efficacy parameters as well as the safety of the combined treatment. This study will consist of two (2) stages. Lead-in Stage, in which the safety and tolerability of the combination will be assessed and confirmed. And the Efficacy Stage, in which patients will be treated with BXCL701 combined with PEMBRO.
    Location: 5 locations

  • A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

    A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.
    Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts

  • Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

    This phase II trial studies the side effects of talabostat and pembrolizumab and to see how well they work for the treatment of solid cancers that have spread to other places in the body (advanced). Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talabostat and pembrolizumab may help control the disease.
    Location: M D Anderson Cancer Center, Houston, Texas